Unknown

Dataset Information

0

Evolutionary Pressure against MHC Class II Binding Cancer Mutations.


ABSTRACT: The anti-cancer immune response against mutated peptides of potential immunological relevance (neoantigens) is primarily attributed to MHC-I-restricted cytotoxic CD8+ T cell responses. MHC-II-restricted CD4+ T cells also drive anti-tumor responses, but their relation to neoantigen selection and tumor evolution has not been systematically studied. Modeling the potential of an individual's MHC-II genotype to present 1,018 driver mutations in 5,942 tumors, we demonstrate that the MHC-II genotype constrains the mutational landscape during tumorigenesis in a manner complementary to MHC-I. Mutations poorly bound to MHC-II are positively selected during tumorigenesis, even more than mutations poorly bound to MHC-I. This emphasizes the importance of CD4+ T cells in anti-tumor immunity. In addition, we observed less inter-patient variation in mutation presentation for MHC-II than for MHC-I. These differences were reflected by age at diagnosis, which was correlated with presentation by MHC-I only. Collectively, our results emphasize the central role of MHC-II presentation in tumor evolution.

SUBMITTER: Marty Pyke R 

PROVIDER: S-EPMC6482006 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evolutionary Pressure against MHC Class II Binding Cancer Mutations.

Marty Pyke Rachel R   Thompson Wesley Kurt WK   Salem Rany M RM   Font-Burgada Joan J   Zanetti Maurizio M   Carter Hannah H  

Cell 20180920 2


The anti-cancer immune response against mutated peptides of potential immunological relevance (neoantigens) is primarily attributed to MHC-I-restricted cytotoxic CD8<sup>+</sup> T cell responses. MHC-II-restricted CD4<sup>+</sup> T cells also drive anti-tumor responses, but their relation to neoantigen selection and tumor evolution has not been systematically studied. Modeling the potential of an individual's MHC-II genotype to present 1,018 driver mutations in 5,942 tumors, we demonstrate that  ...[more]

Similar Datasets

| S-EPMC2212666 | biostudies-literature
| S-EPMC3186872 | biostudies-literature
| PRJEB15527 | ENA
| S-EPMC8356565 | biostudies-literature
| S-EPMC5421785 | biostudies-literature
| S-EPMC2875769 | biostudies-literature
| S-EPMC5925780 | biostudies-literature
| S-EPMC5159193 | biostudies-literature
| S-EPMC3929436 | biostudies-literature
| S-EPMC7465434 | biostudies-literature